CJC-1295 vs IGF-1 LR3 compared: how each peptide works, half-life, typical dosing, side effects, and why neither is FDA-approved for human use in the US.
CJC-1295 and IGF-1 LR3 are not the same kind of compound, so comparing them is really a question of where each one acts. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog that signals the pituitary to release more growth hormone, while IGF-1 LR3 is a long-acting analog of insulin-like growth factor 1 that binds IGF-1 receptors directly. Neither is FDA-approved for human use in the United States, and both are sold almost exclusively as research chemicals.
What CJC-1295 Does
CJC-1295 is a synthetic peptide modeled on GHRH. It binds GHRH receptors on pituitary cells and increases the size and frequency of growth hormone pulses, which in turn nudges the liver to produce more IGF-1. That indirect route is the single most important difference between the two peptides.
There are two versions commonly discussed:
- CJC-1295 with DAC — a Drug Affinity Complex binds the peptide to albumin, stretching its half-life to roughly six to eight days.
- CJC-1295 without DAC (often called Mod GRF 1-29) — a much shorter half-life of about 30 minutes, which is why it is usually paired with a GHRP such as ipamorelin.
Because CJC-1295 works upstream, its effect depends on a pituitary that still responds normally. Feedback loops, sleep, stress, and nutrition all influence how much growth hormone is actually released.
What IGF-1 LR3 Does
IGF-1 LR3 ("long arginine 3") is a modified form of IGF-1 with an amino acid substitution and a 13-amino-acid extension. Those changes slow clearance so the peptide lasts roughly 20 to 30 hours instead of minutes, and they reduce its affinity for IGF-binding proteins, leaving more of it free and active.
IGF-1 LR3 skips the pituitary entirely. It docks onto IGF-1 receptors on muscle, bone, and other tissues and triggers growth, glucose uptake, and cell-survival signaling. It also suppresses natural growth hormone release through negative feedback, which is a key point when people consider stacking it.
CJC-1295 vs IGF-1 LR3 at a Glance
| Feature | CJC-1295 (with DAC) | IGF-1 LR3 |
|---|---|---|
| Compound type | GHRH analog | IGF-1 analog |
| Primary target | Pituitary GHRH receptors | IGF-1 receptors in tissue |
| Half-life | About 6–8 days | About 20–30 hours |
| Effect on natural GH | Increases pulsatile GH release | Suppresses GH via feedback |
| Injection frequency in community protocols | Once or twice weekly | Daily |
| Blood sugar impact | Usually minimal | Hypoglycemia is a real risk |
| FDA status | Not approved for human use | Not approved; mecasermin is the approved IGF-1 drug |
Key Differences That Matter
Upstream versus downstream. CJC-1295 asks the body to make more of its own growth hormone. IGF-1 LR3 delivers the downstream signal whether the body wants it or not, which makes dosing far less forgiving.
Half-life and convenience. A weekly injection schedule looks appealing for CJC-1295 with DAC, but that also means a mistake takes days to clear. IGF-1 LR3 clears faster and is easier to stop, but it requires daily administration.
Blood sugar. IGF-1 receptors are closely tied to insulin signaling, and IGF-1 LR3 can drive blood glucose down. CJC-1295 does not carry the same acute hypoglycemia risk, though elevated growth hormone over time can affect insulin sensitivity.
Evidence base. CJC-1295 has small, short human studies on pharmacokinetics and IGF-1 levels, but no large trials. IGF-1 LR3 has essentially no human clinical data at all. Many researchers also look into cjc-1295 vs bpc-157 when they want to compare two compounds with very different targets, since BPC-157 is studied for tissue repair rather than hormone signaling.
Can You Take IGF-1 LR3 and CJC-1295 Together?
A common forum question is can you take igf-1 lr3 and cjc-1295 together, and the honest answer is that no human trial has tested the combination. In theory the two compounds pull in opposite directions: IGF-1 LR3 raises circulating IGF-1 and suppresses growth hormone, while CJC-1295 tries to increase growth hormone output.
Community discussions of cjc-1295 ipamorelin igf-1 lr3 stacks usually separate the compounds into different phases for that reason. Some people run a GHRH and GHRP combo first and add IGF-1 LR3 later, while others avoid overlapping them entirely.
Another comparison that comes up often is aod 9604 vs cjc 1295, where AOD 9604 is a fat-metabolism fragment of growth hormone rather than a secretagogue, and cjc-1295 ipamorelin vs tesamorelin, which sets an unapproved research stack against an FDA-approved drug.
What Has Actual Clinical Data
Tesamorelin is FDA-approved for HIV-associated lipodystrophy, and mecasermin (Increlex) is approved for severe primary IGF-1 deficiency. Sermorelin was once approved in the US but is no longer marketed as a brand-name drug. Neither CJC-1295 nor IGF-1 LR3 holds that status.
That gap matters, because approved drugs come with known dosing ranges, monitored manufacturing, and published safety data. Research peptides do not.
Side Effects, Safety, and Legal Status
Both peptides are sold as research chemicals, and neither is approved by the FDA for human injection. Buying them for personal use sits in a gray-to-illegal space, and product quality varies widely between vendors.
- CJC-1295: injection-site reactions, water retention, joint aches, carpal tunnel symptoms, and possible effects on glucose metabolism from prolonged growth hormone elevation.
- IGF-1 LR3: hypoglycemia, injection-site irritation, and concerns about tissue overgrowth with long-term use, since IGF-1 is a potent growth and survival signal.
Anyone considering these compounds should discuss it with a licensed healthcare professional first, especially with diabetes, a history of cancer, or medications that affect blood sugar. Self-dosing research peptides carries real risk that no forum post can quantify.
Bottom Line
CJC-1295 is an upstream GHRH analog that raises your own growth hormone, and IGF-1 LR3 is a downstream IGF-1 receptor agonist that bypasses the pituitary entirely. CJC-1295 is not FDA-approved for human use, and IGF-1 LR3 is not either, though FDA-approved IGF-1 therapy exists in the form of mecasermin.
If the goal is a legitimate medical evaluation of growth hormone or IGF-1 status, the right first step is blood work and a physician, not a research peptide. The two compounds are not interchangeable, and stacking them has no clinical evidence behind it.
Frequently Asked Questions
Is CJC-1295 the same as IGF-1 LR3?
No. CJC-1295 is a GHRH analog that stimulates the pituitary to release more growth hormone, while IGF-1 LR3 is a modified IGF-1 that binds IGF-1 receptors directly in muscle and other tissue. CJC-1295 raises IGF-1 indirectly, and IGF-1 LR3 delivers the signal itself while suppressing natural growth hormone release.
Can you take CJC-1295 and IGF-1 LR3 together?
There is no human clinical trial testing the combination, and the two compounds work against each other on the GH and IGF-1 axis. IGF-1 LR3 suppresses natural growth hormone release, which can blunt the effect of CJC-1295. Anyone considering it should speak with a healthcare professional first.
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not FDA-approved for human use and is sold as a research chemical. The only approved IGF-1 product in the United States is mecasermin (Increlex), which is prescribed for children with severe primary IGF-1 deficiency.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.